Three things to know:
1. A key driver of the market is the increasing prevalence of musculoskeletal diseases and disorders.
2. The growing use of nanoparticles in orthopedic bioimplants will significantly propel the market forward over the forecast period.
3. The joint replacement segment held the largest market share in 2017, accounting for around 33 percent. This segment is expected to dominate the market throughout the forecast period.
More articles on biologics:
Bioventus launches biphasic orthopedic, spine bone graft: 3 insights
Biointegrative orthopedic fixation material receives FDA clearance: 5 things to know
Louisiana spine surgeon adopts stem cell therapy options: 5 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
